RBC Capital lowers Pharvaris stock price target on model adjustments

RAPIDe-3 Phase 3 for deucrictibant met its primary endpoint and all 11 secondary endpoints, and RBC sees the XR formulation delivering ≥70% attack-rate reductions. RBC cut its price target slightly to $51 from $52 but maintained an Outperform, while Oppenheimer reiterated Outperform with a $50 target; RBC projects up to 80% upside if Q3 2026 topline is successful. Shares are up ~100% over the past year, trading near a 52-week high of $29.85 with a $1.87B market cap.

Analysis

Pharvaris is trading as a binary product-development story where the XR readout and subsequent label expectations will drive a multi-trajectory revaluation. If XR demonstrates materially better attack-rate reduction and safety versus incumbent injectables, payers will face a clear substitutability decision that can accelerate uptake over 12–36 months; conversely, anything short of a step-change in efficacy or an unexpected safety signal compresses addressable pricing and pushes commercialization timelines out by 18–36 months.

Second-order beneficiaries: CDMOs with oral XR experience, specialty pharma sales platforms focused on HAE, and diagnostics/CV monitoring vendors that participate in post-launch real-world evidence programs stand to capture outsized revenue if launch execution is smooth. Second-order losers: existing injectable franchises and plasma-supply-dependent players could see unit-volume pressure and margin compression as payers substitute to an oral on-demand option, raising negotiation leverage and rebate demands.

Tail risks cluster around reimbursement and manufacturing scale. A single pivotal readout can shift valuation sharply within days, but durable commercial success requires favorable pricing negotiations with specialty pharmacies and PBMs plus low-cost scalable XR manufacture — each a 6–24 month gating item. Near-term reversals are most likely from slower-than-expected XR durability data, unexpected adverse events, or a tougher-than-expected label that limits prophylaxis claims and reduces TAM per patient.

Consensus is tilted toward favorable readout outcomes; that narrative underestimates execution risk in distribution and payer contracting. The market may be overassigning revenue multiple expansion to the readout itself rather than to multi-year uptake mechanics — meaning a positive trial could be necessary but not sufficient for a sustained re-rating without clear commercialization milestones and early launch uptake signals.

Key Decisions for Investors

• Long PHVS equity (1–2% portfolio) into the XR readout window (6–12 months): size small given binary risk; target a 50–100% upside on a clean readout and label clarity, hedge with a 25–30% trailing stop or buy protective puts if position exceeds 2% of portfolio risk.
• Buy a defined-risk options spread on PHVS: purchase Jan-2027 50% OTM calls and sell Jan-2028 100% OTM calls to create a debit call spread — costs limited, upside retained through the first 6–12 months post-readout; roll if positive signal to capture launch optionality.
• Pair trade: long PHVS / short an incumbent injectable HAE franchise (eg, large-cap with HAE revenue exposure) sized 1:0.5 — directional hedge for product substitution risk with a 12–24 month horizon; take profits if PHVS outperforms by >40% or if payer contracts published indicate limited switching.
• Pre-readout conservative: remain flat-to-small exposure and use any >20% post-release gap-up as opportunity to sell 30–50% into strength and buy back on pullbacks — preserves optionality while monetizing headline-driven volatility.